Pharmaceutical Intermediates Market | USD 57.65 Billion by 2034
The pharmaceutical intermediates market size was exhibited at USD 35.56 billion in 2024 and is projected to hit around USD 57.65 billion by 2034, growing at a CAGR of 4.95% during the forecast period 2025 to 2034.
The U.S. pharmaceutical intermediates market size reached USD 9.3 billion in 2024 and is anticipated to be worth around USD 15.1 billion by 2034, poised to grow at a CAGR of 4.5% from 2025 to 2034.
Based on region, the North America dominated the global pharmaceutical intermediates market in 2024, in terms of revenue and is estimated to sustain its dominance during the forecast period. North America is dominating market due to the presence of numerous pharmaceutical companies, research centers and laboratories, and rapidly growing CMOs & CROs in the US and Canada. Further, rising investments by the government and private players to boost the growth of the biopharmaceutical industry is expected to sustain the dominating position of North America throughout the forecast period.
On the other hand, Asia Pacific is estimated to be the most opportunistic market during the forecast period. The rising investments by the market players to set up manufacturing facilities in the nations like China, India, Japan, South Korea, and Singapore owing to the easy and cheap availability of factors of production and favorable government policies is boosting the growth of the pharmaceutical intermediates market during the forecast period.
| Report Coverage | Details |
| Market Size in 2025 | USD 37.32 Billion |
| Market Size by 2034 | USD 57.65 Billion |
| Growth Rate From 2025 to 2034 | CAGR of 4.95% |
| Base Year | 2024 |
| Forecast Period | 2025-2034 |
| Segments Covered | Product, Application, and End User |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional scope | North America; Europe; Asia Pacific; Latin America; MEA |
| Key Companies Profiled | The major players operating in the pharmaceutical intermediates market are BASF SE, Aceto Corporation, Sanofi SAIS, Chiracon GmbH, Yin-sheng Bio-tech Co. Ltd., Dishman Group, Green Vision Life Sciences, Midas Pharma GmbH, Vertellus Holdings LLC., Lonza Group. |
Based on product, the bulk drug intermediates segment accounted largest revenue share in 2024. Bulk drug intermediates are extensively used for making active pharmaceutical ingredient (API). API is the key ingredient used in the manufacturing of drugs that gives the desired therapeutic effect. Moreover, government initiatives to promote and develop bulk drug parks is estimated to drive the growth of this segment. For instance, the Department of Pharmaceuticals prioritizes a list of 56 APIs under Make-in-India initiative.
On the other hand, the custom intermediates is expected to be the fastest-growing segment during the forecast period. Custom drug intermediates means customization of specific molecule up to a certain scale to get the desired therapeutic affect or results. This segment is slowly gaining traction in the market.
Based on application, the analgesics segment accounted for around 31.0% of the global pharmaceutical intermediates market and is expected to sustain its dominance in near future. Analgesics are extensively used for the pain relief. The rising prevalence of chronic ailments such as arthritis, cancer, and cardiovascular diseases is boosting the growth of this segment.
On the other hand, the anti cancer drugs is expected to grow at a rapid rate during the forecast period. This is owing to the rising prevalence of cancer among the global population. According to the International Agency for Research on Cancer, in 2020, around 19.3 million new cancer cases and 10 million cancer deaths were reported across the globe. Therefore, this segment is estimated to be the fastest-growing segment.
Based on end user, the CROs/CMOs segment lead the global pharmaceutical intermediates market in 2024, in terms of revenue and is estimated to sustain its dominance during the forecast period. The rising penetration and rapid growth of the contract manufacturing organizations and contract research organizations have significantly boosted the demand for the pharmaceutical intermediates for the production and research purposes of drugs.
On the other hand, research laboratories are expected to grow at a rapid rate during the forecast period. The rising private investments in the research activities in the pharmaceutical industry for the development of new drugs is estimated to drive the growth of this segment.
The market is moderately fragmented with the presence of several local companies. These market players are striving to gain higher market share by adopting strategies, such as investments, partnerships, and acquisitions & mergers. Companies are also spending on the development of improved products. Moreover, they are also focusing on maintaining competitive pricing.
The various developmental strategies like acquisitions and mergers fosters market growth and offers lucrative growth opportunities to the market players.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the Pharmaceutical Intermediates Market
By Product
By Application
By End User
By Regional
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Pharmaceutical Intermediates Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Pharmaceutical Intermediates Market, by Product Type
8.1.1. Chemical Intermediates
8.1.1.1. Market Revenue and Forecast
8.1.2. Bulk Drug Intermediates
8.1.2.1. Market Revenue and Forecast
8.1.3. Custom Intermediates
8.1.3.1. Market Revenue and Forecast
9.1. Pharmaceutical Intermediates Market, by Application
9.1.1. Analgesics
9.1.1.1. Market Revenue and Forecast
9.1.2. Ant-inflammatory Drug
9.1.2.1. Market Revenue and Forecast
9.1.3. Cardiovascular Drugs
9.1.3.1. Market Revenue and Forecast
9.1.4. Anti-Cancer Drugs
9.1.4.1. Market Revenue and Forecast
9.1.5. Anti-Diabetic Drugs
9.1.5.1. Market Revenue and Forecast
9.1.6. Others
9.1.6.1. Market Revenue and Forecast
10.1. Pharmaceutical Intermediates Market, by End User
10.1.1. Biotech & Pharma Companies
10.1.1.1. Market Revenue and Forecast
10.1.2. Research Laboratory
10.1.2.1. Market Revenue and Forecast
10.1.3. CMO/CRO
10.1.3.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Product
11.1.2. Market Revenue and Forecast, by Application
11.1.3. Market Revenue and Forecast, by End User
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Product
11.1.4.2. Market Revenue and Forecast, by Application
11.1.4.3. Market Revenue and Forecast, by End User
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Product
11.1.5.2. Market Revenue and Forecast, by Application
11.1.5.3. Market Revenue and Forecast, by End User
11.2. Europe
11.2.1. Market Revenue and Forecast, by Product
11.2.2. Market Revenue and Forecast, by Application
11.2.3. Market Revenue and Forecast, by End User
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Product
11.2.4.2. Market Revenue and Forecast, by Application
11.2.4.3. Market Revenue and Forecast, by End User
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Product
11.2.5.2. Market Revenue and Forecast, by Application
11.2.5.3. Market Revenue and Forecast, by End User
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Product
11.2.6.2. Market Revenue and Forecast, by Application
11.2.6.3. Market Revenue and Forecast, by End User
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Product
11.2.7.2. Market Revenue and Forecast, by Application
11.2.7.3. Market Revenue and Forecast, by End User
11.3. APAC
11.3.1. Market Revenue and Forecast, by Product
11.3.2. Market Revenue and Forecast, by Application
11.3.3. Market Revenue and Forecast, by End User
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Product
11.3.4.2. Market Revenue and Forecast, by Application
11.3.4.3. Market Revenue and Forecast, by End User
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Product
11.3.5.2. Market Revenue and Forecast, by Application
11.3.5.3. Market Revenue and Forecast, by End User
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Product
11.3.6.2. Market Revenue and Forecast, by Application
11.3.6.3. Market Revenue and Forecast, by End User
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Product
11.3.7.2. Market Revenue and Forecast, by Application
11.3.7.3. Market Revenue and Forecast, by End User
11.4. MEA
11.4.1. Market Revenue and Forecast, by Product
11.4.2. Market Revenue and Forecast, by Application
11.4.3. Market Revenue and Forecast, by End User
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Product
11.4.4.2. Market Revenue and Forecast, by Application
11.4.4.3. Market Revenue and Forecast, by End User
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Product
11.4.5.2. Market Revenue and Forecast, by Application
11.4.5.3. Market Revenue and Forecast, by End User
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Product
11.4.6.2. Market Revenue and Forecast, by Application
11.4.6.3. Market Revenue and Forecast, by End User
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Product
11.4.7.2. Market Revenue and Forecast, by Application
11.4.7.3. Market Revenue and Forecast, by End User
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Product
11.5.2. Market Revenue and Forecast, by Application
11.5.3. Market Revenue and Forecast, by End User
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Product
11.5.4.2. Market Revenue and Forecast, by Application
11.5.4.3. Market Revenue and Forecast, by End User
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Product
11.5.5.2. Market Revenue and Forecast, by Application
11.5.5.3. Market Revenue and Forecast, by End User
12.1. Aceto Corporation
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. BASF SE
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Chiracon GmbH
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Yin-sheng Bio-tech Co. Ltd.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Dishman Group
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Green Vision Life Sciences
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Midas Pharma GmbH
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Sanofi SAIS
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Vertellus Holdings LLC.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Lonza Group
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers